Fig. 5.

Anti-CD137 and anti-OX40-producing microcapsules can be employed concomitantly. Mice with established CT26 tumors for 8 days were treated with the indicated subcutaneous microcapsules or purified monoclonal antibodies given as single doses. Individual follow-up of tumor sizes and the fraction of mice in each group that underwent complete rejection are given